These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 18557229)

  • 21. Market power, collusion, and exclusion in health care antitrust enforcement.
    Spears JM
    J Med Assoc Ga; 1992 Sep; 81(9):499-507. PubMed ID: 1402429
    [No Abstract]   [Full Text] [Related]  

  • 22. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
    Jones GH; Carrier MA; Silver RT; Kantarjian H
    Blood; 2016 Mar; 127(11):1398-402. PubMed ID: 26817958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 24. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of drug industry marketing practices on formularies questioned by federal agencies.
    Gatty B
    Hosp Formul; 1994 Nov; 29(11):786, 785. PubMed ID: 10138576
    [No Abstract]   [Full Text] [Related]  

  • 26. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court.
    Hawkes N
    BMJ; 2012 Dec; 345():e8396. PubMed ID: 23230222
    [No Abstract]   [Full Text] [Related]  

  • 27. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 29. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct reimbursement and the conspiracy of silence.
    Plunkett LR
    N Y State Dent J; 1997 Oct; 63(8):6-9. PubMed ID: 9375505
    [No Abstract]   [Full Text] [Related]  

  • 32. Generic drugs get a life.
    Cole RT; Saputo D
    Mark Health Serv; 2003; 23(1):18-23. PubMed ID: 12645433
    [No Abstract]   [Full Text] [Related]  

  • 33. Antitrust ruling may deter hospitals from challenging the market leader.
    Horty J
    Mod Healthc; 1986 May; 16(11):91-2. PubMed ID: 10276445
    [No Abstract]   [Full Text] [Related]  

  • 34. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 35. Understanding antitrust: focus on the relevant market.
    Enders RJ
    Healthc Financ Manage; 1986 Feb; 40(2):25-32. PubMed ID: 10275004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Market definition key to antitrust regulations.
    Solovy A
    Hospitals; 1989 Oct; 63(19):74. PubMed ID: 2793118
    [No Abstract]   [Full Text] [Related]  

  • 37. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
    Margolis RE
    Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
    [No Abstract]   [Full Text] [Related]  

  • 38. The Orphan Drug Act: an engine of innovation? At what cost?
    Rohde DD
    Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
    [No Abstract]   [Full Text] [Related]  

  • 39. Authorized generic drugs, price competition, and consumers' welfare.
    Berndt ER; Mortimer R; Bhattacharjya A; Parece A; Tuttle E
    Health Aff (Millwood); 2007; 26(3):790-9. PubMed ID: 17485758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.